NCT00268593 Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer Status COMPLETED Phase PHASE2
NCT00258388 Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy Status COMPLETED Phase PHASE2
NCT00255606 Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer Status COMPLETED Phase PHASE3
NCT00238368 Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant Status COMPLETED Phase PHASE2
NCT00227591 Lenalidomide and Prednisone in Treating Patients With Myelofibrosis Status COMPLETED Phase PHASE2
NCT00225173 Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease Status TERMINATED Phase PHASE2
NCT00217425 Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms Status COMPLETED Phase PHASE2
NCT00211185 A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma Status COMPLETED Phase PHASE2
NCT00209209 Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL Status UNKNOWN Phase PHASE3
NCT00203047 Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate Status TERMINATED Phase PHASE4
NCT00195429 A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients Status COMPLETED Phase PHASE4
NCT00194987 A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia Status COMPLETED Phase PHASE2/PHASE3
NCT00193479 Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma Status COMPLETED Phase PHASE2
NCT00187122 Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma Status COMPLETED Phase NA
NCT00182741 Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer Status COMPLETED Phase PHASE2